127073-84-1

Basic information

• Product Name: (R)-3-iodo-1-phenyl-1-propanol
• Synonyms: (R)-3-iodo-1-phenyl-1-propanol
• CAS NO: 127073-84-1
• Molecular Weight: 262.09
• Mol File: 127073-84-1.mol

Chemical Properties

• CAS DataBase Reference: (R)-3-iodo-1-phenyl-1-propanol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-iodo-1-phenyl-1-propanol(127073-84-1)
• EPA Substance Registry System: (R)-3-iodo-1-phenyl-1-propanol(127073-84-1)

Safety Data

• Hazardous Substances Data: 127073-84-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-3-iodo-1-phenyl-1-propanol is used as a chiral building block for the synthesis of various pharmaceuticals. Its asymmetric carbon center allows for the creation of specific stereoisomers, which can be crucial in the development of drugs with targeted effects and reduced side effects.
Used in Agrochemical Industry:
In the agrochemical industry, (R)-3-iodo-1-phenyl-1-propanol is utilized as a key component in the synthesis of certain agrochemicals. Its stereochemical properties enable the production of compounds with specific biological activities, contributing to the development of more effective and targeted agrochemical products.
Used in Chemical Research:
(R)-3-iodo-1-phenyl-1-propanol is also used in chemical research, particularly in the field of radiochemistry. The presence of the iodine atom makes it a potentially valuable tool for radiochemical labeling and related research applications, facilitating the study of chemical reactions and processes at the molecular level.
Used in Organic Synthesis:
(R)-3-iodo-1-phenyl-1-propanol is employed as an intermediate in organic synthesis, where its unique structural features can be exploited to construct a wide range of complex organic molecules. Its versatility in synthesis makes it a valuable asset in the development of new chemical products and materials.

Upstream product

• 103548-16-9 (R)-3-phenyl-1,3-dihydroxypropane 
• 936-59-4 3-chloropropiophenone 
• 100306-33-0 (1R)-3-chloro-1-phenylpropanol 

Downstream Products

• 168465-69-8 (R)-α-(2-azidoethyl)benzenemethanol 
• 319924-88-4 (R)-6-methyl-3,4-dihydro-2-phenyl-2H-1-benzopyran 
• 319924-88-4 (S)-6-methyl-3,4-dihydro-2-phenyl-2H-1-benzopyran 
• 1132755-87-3 (R)-3,4-dihydro-2-phenyl-2H-1-benzopyran 
• 157968-59-7 (S)-3,4-dihydro-2-phenyl-2H-1-benzopyran 
• 54910-89-3 (R)-fluoxetine 
• 695229-16-4 C₁₆H₁₄INOS 
• 114247-09-5 (R)-fluoxetine hydrochloride 
• 570384-27-9 [4-(3-amino-1-phenyl-propoxy)-phenyl]-p-tolyl-methanone 
• 138750-31-9 (1R)-3-amino-1-phenyl-1-propanol 
• 155675-18-6 3-Phenyl-propionic acid (R)-3-iodo-1-phenyl-propyl ester 
• 115290-81-8 (R)-N-methyl-3-phenyl-3-hydroxypropylamine 
• 155675-30-2 (R)-3-Benzyloxy-butyric acid (R)-3-iodo-1-phenyl-propyl ester 

Relevant articles and documents

A method for preparing optically active 3-amino-1-phenylpropanol derivatives as an intermediate and a method for preparing optically active pharmaceutical products using the same

The present invention relates to a method for preparing a 3-amino-1-phenylpropanol derivative having (R) or (S) optical activity with 80% or more of an enantiomeric excess (ee), which includes a step of performing an asymmetric reduction reaction in the presence of a spiroborate ester catalyst and a hydrogen donor. The invention also relates to a method for preparing an optically active pharmaceutical product, which includes a step of preparing a (R)- or (S)-3-amino-1-phenylpropanol derivative, that is an intermediate, by using the catalyst.(AA) 3-amino-1-phenylpropanol(BB) Tomoxetine(CC) Nisoxetine(DD) FluoxetineCOPYRIGHT KIPO 2016

HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES

New hydroxy aliphatic substituted phenyl aminoalkyl ether compounds of formula (I), compositions thereof and their use as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits.

Copper(ii)-catalyzed enantioselective hydrosilylation of halo-substituted alkyl aryl and heteroaryl ketones: Asymmetric synthesis of (R)-fluoxetine and (S)-duloxetine

A set of reaction conditions has been established to facilitate the non-precious copper-catalyzed enantioselective hydrosilylation of a number of structurally diverse β-, γ- or ε-halo-substituted alkyl aryl ketones and α-, β- or γ-halo-substituted alkyl heteroaryl ketones under air to afford a broad spectrum of halo alcohols in high yields and good to excellent enantioselectivities (up to 99% ee). The developed procedure has been successfully applied to the asymmetric synthesis of antidepressant drugs (R)-fluoxetine and (S)-duloxetine, which highlighted its synthetic utility.

Asymmetric dehydration of β-hydroxy esters and application to the syntheses of flavane derivatives

Catalytic asymmetric dehydration of β-aryl or alkyl substituted β-hydroxy esters via kinetic resolution has been investigated. A brief survey of 10 different chiral ligands is conducted to examine the effects of chiral ligand structure on selectivity of t

7-PHENYL-ISOQUINOLINE-5-SULFONYLAMINO DERIVATIVES AS INHIBITORS OF AKT (PROTEINKINASE B)

The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.

PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS

There is provided a heretoaryloxy/thio 3-substituted propanamine compound of formula (I) wherein A is selected from -O- and -S-; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C1-C4 alkyl, and C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, and thienopyridyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; Z is selected from H, OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl C1-C6 alkyl; R1 and R2 are each independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereof.

[3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter.

The synthesis of NPTS, 6, a potent inhibitor of the type 1 glycine transporter (GlyT1) is described, as well as preparation of 6 in optically active and tritiated form for use as a radioligand for affinity displacement assay of GlyT1.

ENANTIOSELECTIVE AND PRACTICAL SYNTHESES OF R- AND S-FLUOXETINES

An efficient synthetic route to either R- or S-fluoxetine is described which depends on the use of a chiral, enzyme-like catalyst (chemzyme) to establish the stereocenter and which makes these important therapeutic agents readily available in enantiomerically pure form.